Name : PARK9/ATP13A2 Antibody, Cy7 Conjugated
Supplier : BIOSS PRIMARY CONJUGATED ANTIBODIES 1
Price :350
SKU : GEN2051205983
| Long name | Cy7 Conjugated, PARK9/ATP13A2 Polyclonal Antibody |
| Category | Conjugated Primary Antibodies |
| Conjugation | Cy7 |
| Host Organism | Rabbit (Oryctolagus cuniculus) |
| Target Antigen | PARK9/ATP13A2 |
| Specificity | This is a highly specific antibody against PARK9/ATP13A2 |
| Modification | Unmodified |
| Modification site | None |
| Clonality | Polyclonal |
| Clone | Polyclonal antibody |
| Concentration | 1ug per 1ul |
| Subcellular location | Extracellular |
| Source | KLH conjugated synthetic peptide derived from human ATP13A2 |
| Tested applications | IF(IHC-P) |
| Recommended dilutions | IF(IHC-P)(1:50-200) |
| Crossreactivity | Mouse, Rat, Human |
| Crossreactive species details | not every possible cross-reactivity is known, Due to limited amount of testing and knowledge |
| Antigen background | ATP13A2 functions to catalyze the conversion of ATP to ADP and a free phosphate, Defects in the gene encoding ATP13A2 are the cause of Kufor-Rakeb syndrome (KRS), Expressed as multiple alternative spliced isoforms, The ATP13A2 gene maps to human chromosome 1, a rare hereditary type of Parkinsonâ, contains over 3, thereby participating in the active transport of ions across cellular membranes, which spans 260 million base pairs, &euro, &trade, 000 genes and comprises nearly 8% of the human genome, 180 amino acid multi-pass membrane protein that belongs to the P5 subfamily of ATPases which play an important role in the transportation of inorganic cations, ATP13A2 is a 1, s disease that exhibits juvenile onset and is characterized by neurodegeneration and dementia |
| Purification method | This antibody was purified via Protein A |
| Storage conditions | 50% glycerol and 0, Store refrigerated at 2 to 8 degrees Celcius for up to 1 year, 09% sodium azide, Keep the antibody in an aqueous buffered solution containing 1% BSA |
| Excitation Emission | 743nm/767nm |
| Synonyms | HSA9947 CLN12 |
| Properties | C, C for long term storage and for short term at + 5°, If you buy Antibodies supplied by Bioss Primary Conjugated Antibodies they should be stored frozen at - 24° |
| Conjugated | These antibodies are excite for emission at 650 nm and detected at a 676 nm wavelengths |
| Gene target | PARK9/ATP13A2 Conjugated |
| Short name | Conjugated, PARK9/ATP13A2 Antibody |
| Technique | antibodies against human proteins, antibodies for, antibody Conjugates, Antibody |
| Label | Cy7 |
| Alternative name | cyanine 7 coupled, PARK9/ATP13A2 (Antibody to) |
| Alternative technique | antibodies |
| Identity | 30213 |
| Gene | ATP13A2 |
| Long gene name | ATPase 13A2 |
| Synonyms gene | PARK9 |
| Synonyms gene name | Parkinson disease (autosomal recessive) 9 (Kufor-Rakeb syndrome) ATPase type 13A2 |
| Locus | 1p36, 13 |
| Discovery year | 2005-01-12 |
| GenBank acession | AL354615 |
| Entrez gene record | 23400 |
| Pubmed identfication | 15381061 16964263 |
| RefSeq identity | NM_022089 |
| Classification | Parkinson disease associated genes ATPase orphan transporters |
| Havana BLAST/BLAT | OTTHUMG00000002293 |
| Locus Specific Databases | LRG_834 |